Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia

Published:2019-04-02 Issue:13 Volume:25 Page:3974-3985
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Manna Alak,Aulakh Sonikpreet,Jani Prachi,Ahmed Salman,Akhtar Sharoon,Coignet Marie,Heckman Michael,Meghji Zahara,Bhatia Kirtipal,Sharma Aarushi,Sher Taimur,Alegria Victoria,Malavasi Fabio^ORCID,Chini Eduardo N.,Chanan-Khan Asher,Ailawadhi Sikander,Paulus Aneel

Funder

Daniel Foundation of Alabama

Predolin Foundation

University of Iowa

Mayo Clinic

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity;Molecular Therapy: Oncology;2024-09

2. Bruton Tyrosine Kinase Inhibition Decreases Inflammation and Differentially Impacts Phagocytosis and Cellular Metabolism in Mouse- and Human-derived Myeloid Cells;ImmunoHorizons;2024-09-01

3. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08

4. CD38/NAD+ glycohydrolase and associated antigens in chronic lymphocytic leukaemia: From interconnected signalling pathways to therapeutic strategies;Biochimie;2024-07

5. Human serum albumin-based drug-free macromolecular therapeutics induce apoptosis in chronic lymphocytic leukemia patient cells by crosslinking of CD20 and/or CD38 receptors;Drug Delivery and Translational Research;2024-05-27